Human TRACP-5b(Tartrate Resistant Acid Phosphatase 5b) ELISA Kit (E-EL-H1551)

This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human TRACP-5b. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human TRACP-5b and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human TRACP-5b, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human TRACP-5b. You can calculate the concentration of Human TRACP-5b in the samples by comparing the OD of the samples to the standard curve.

ADAMTS13 (von Willebrand factor-cleaving protease, VWFCP) is a multidomain secreted zinc metalloprotease synthesized mainly in the liver. Its domain organization comprises a metalloproteinase catalytic domain, a disintegrin-like domain, thrombospondin type 1 repeats, a cysteine-rich and spacer region and two C-terminal CUB domains, and von Willebrand factor (VWF) is its only known physiological substrate. ADAMTS13 cleaves VWF within its A2 domain, thereby controlling the size of circulating VWF multimers and preventing spontaneous platelet adhesion and aggregation under the high shear stress of the microcirculation, which is essential for normal hemostasis. When cleavage is impaired by inherited deficiency or inhibitory autoantibodies, unusually large VWF multimers accumulate on the endothelial surface and trigger inappropriate platelet clumping with consumptive thrombocytopenia, microvascular thrombosis and tissue ischemia. Severe deficiency of ADAMTS13 activity causes thrombotic thrombocytopenic purpura (TTP), and determination of enzyme activity together with inhibitory autoantibodies is central to the diagnosis, differential diagnosis and monitoring of TTP. Reduced activity also accompanies other thrombotic, inflammatory and liver-related states, and quantitative measurement of ADAMTS13 supports research on hemostasis, microvascular thrombosis and thrombotic microangiopathy.